• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Steris shares drop on Q1 swing-and-miss, lowered outlook

Steris shares drop on Q1 swing-and-miss, lowered outlook

August 2, 2022 By Jim Hammerand

SterisSteris (NYSE:STE) posted first-quarter results today that fell short of the consensus forecast on Wall Street and reduced its outlook for the rest of the year, despite swinging to a profit from a loss a year ago.

The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — reported profits of $111.3 million, or $1.11 per share, on sales of $1.16 billion for the three months ended June 30, 2022. Sales increased 19% compared to the same quarter last year, in which the company reported a $21.8 million loss.

Adjusted to exclude one-time items, earnings per share were $1.90, a penny short of Wall Street, where analysts were looking for EPS of $1.91 on sales of $1.22 billion.

“We are pleased with our operational performance in the quarter, which reflected solid constant currency organic revenue growth despite supply chain challenges,” Steris President and CEO Dan Carestio said in a news release. “Demand for our products remains strong, as evidenced by our significant backlog in healthcare capital equipment. Despite several headwinds, we continue to expect another year of record performance.”

Steris said it expects to log adjusted EPS of $8.40 to $8.60 in fiscal 2023, down from prior guidance of $8.55 to $8.75. Steris also decreased its full-year revenue growth outlook from 12% to 9%, “reflecting the net impact of acquisitions and divestitures as well as approximately $100 million in anticipated negative impact of foreign currency fluctuations.”

The company expects constant currency organic revenue growth of 10%, down from its outlook of 11% at the end of last quarter, citing “ongoing supply chain challenges and procedure volumes somewhat lighter than anticipated.”

STE shares and MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — both closed the day up less than 1%. Steris released its financial results after the markets closed, sending STE shares down nearly 5% to $213.43 in after-hours trading.

Filed Under: Blog, Business/Financial News, MassDevice Earnings Roundup Tagged With: Steris

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Jim Hammerand

Jim Hammerand is the managing editor of Medical Design & Outsourcing. He has more than two decades of journalism experience spanning newspapers, magazines, websites, live events, radio and TV news. For nearly a decade, Hammerand reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then managing editor of the Puget Sound Business Journal in Seattle. He holds a bachelor’s degree in journalism from the University of Minnesota. He is based near Seattle, Washington, where he and his family live. Connect with him on LinkedIn or by email at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy